#1 Clinical Trials Search in Europe

Osteodex

Osteodex, a novel poly-bisphosphonate drug containing dextran, alendronate, and guanidine, is being studied in clinical trials for its potential in treating metastatic castration-resistant prostate cancer (CRPC) and multiple myeloma. These trials aim to evaluate the safety, efficacy, and optimal dosing of Osteodex in patients with these challenging conditions. The studies focus on various aspects, including bone metabolism markers, overall survival, and quality of life improvements.

Table of Contents

What is OSTEODEX?

OSTEODEX, also known as ODX, is an investigational drug being studied for the treatment of advanced prostate cancer and multiple myeloma[1][3]. It is a unique medication called a poly-bisphosphonate, which means it combines several known substances to create a potentially more effective treatment. OSTEODEX contains three main components: dextran, alendronate, and guanidine[1].

How does OSTEODEX work?

OSTEODEX is designed to target and affect bone metabolism, which is the process by which bone tissue is formed and broken down. In diseases like advanced prostate cancer and multiple myeloma, this process can become imbalanced, leading to bone-related complications. OSTEODEX aims to help restore this balance and potentially slow down or stop the progression of bone metastases (cancer that has spread to the bones)[2].

What conditions does OSTEODEX treat?

OSTEODEX is primarily being studied for two main conditions:

  • Metastatic Castration-Resistant Prostate Cancer (CRPC): This is an advanced form of prostate cancer that has spread to other parts of the body (metastasized) and no longer responds to hormone therapy that lowers testosterone[1][2].
  • Multiple Myeloma: This is a type of blood cancer that affects plasma cells, a type of white blood cell found in bone marrow. OSTEODEX is being investigated for patients with relapsed or refractory multiple myeloma, which means the cancer has returned or is not responding to other treatments[3].

OSTEODEX Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of OSTEODEX:

  • Phase I/II trials for metastatic CRPC: These studies aim to determine the maximum tolerable dose and assess the drug’s safety and biological effects[1].
  • Phase II trials for metastatic CRPC: These more advanced studies are comparing different doses of OSTEODEX to evaluate its effectiveness in treating bone metastases[2].
  • Phase IIb trial for metastatic CRPC: This study is comparing OSTEODEX to a placebo to further assess its efficacy and tolerability[4].
  • Phase I/IIa trial for multiple myeloma: This study is evaluating the safety and potential effectiveness of OSTEODEX in patients with relapsed or refractory multiple myeloma[3].

Dosage and Administration

OSTEODEX is administered as an intravenous infusion, which means it is given directly into a vein. The dosage and frequency of administration may vary depending on the specific clinical trial and condition being treated. Some examples include:

  • For CRPC trials: Doses ranging from 0.1 mg/kg to 9.0 mg/kg, given every two or three weeks[1][2].
  • For multiple myeloma trials: Doses of 3.0 mg/kg, 6.0 mg/kg, or 9.0 mg/kg, given every two weeks[3].

The exact dosing regimen will be determined by the healthcare team based on the patient’s individual needs and the specific study protocol.

Potential Benefits of OSTEODEX

While research is still ongoing, OSTEODEX may offer several potential benefits for patients with advanced prostate cancer or multiple myeloma:

  • Improved bone health: OSTEODEX may help slow down or prevent the progression of bone metastases[2].
  • Reduced pain: Some studies are evaluating whether OSTEODEX can help reduce cancer-related bone pain[2].
  • Improved quality of life: By potentially slowing disease progression and reducing symptoms, OSTEODEX may help improve overall quality of life for patients[4].
  • New treatment option: For patients who have not responded to other therapies, OSTEODEX may offer a new treatment possibility[3].

Side Effects and Safety Considerations

As with any medication, OSTEODEX may cause side effects. The clinical trials are carefully monitoring patients for any adverse events. Some potential side effects being evaluated include:

  • Changes in kidney function
  • Abnormalities in blood tests (e.g., changes in blood cell counts, liver function tests, or electrolyte levels)
  • Changes in heart rhythm (as measured by ECG)
  • Other potential side effects that may be identified during the trials

It’s important to note that the safety profile of OSTEODEX is still being established through these clinical trials[1][2][3][4].

Future Research and Development

The development of OSTEODEX is ongoing, with researchers continuing to study its effectiveness and safety in various patient populations. Future research may explore:

  • Long-term effects of OSTEODEX treatment
  • Combination therapies with other cancer treatments
  • Potential use in earlier stages of prostate cancer or other types of cancer that affect bone health
  • Expanded use in multiple myeloma patients

As clinical trials progress, more information will become available about the potential role of OSTEODEX in cancer treatment[1][2][3][4].

Aspect Details
Drug Name Osteodex (ODX)
Composition Poly-bisphosphonate containing dextran, alendronate, and guanidine
Target Conditions Metastatic Castration-Resistant Prostate Cancer (CRPC), Multiple Myeloma
Administration Intravenous infusion
Dosage Range 0.1 mg/kg to 9.0 mg/kg
Frequency Every 2-3 weeks
Primary Objectives Safety, tolerability, maximum tolerable dose, effects on bone metabolism markers
Secondary Objectives Overall survival, PSA response, quality of life, pain management
Trial Phases Phase I/II, Phase IIb
Trial Duration 20-30 weeks (initial treatment and follow-up), up to 24 months (long-term follow-up)

FAQ

  • What is Osteodex and how does it work? Osteodex is a poly-bisphosphonate drug containing three known substances: dextran, alendronate, and guanidine. It is designed to target bone metabolism and potentially slow down or stop the progression of bone metastases in cancers like prostate cancer and multiple myeloma.
  • What types of cancer is Osteodex being studied for? Osteodex is primarily being studied for metastatic castration-resistant prostate cancer (CRPC) and multiple myeloma. These are advanced forms of cancer that often involve bone metastases and are challenging to treat.
  • How is Osteodex administered in clinical trials? In the clinical trials, Osteodex is administered as an intravenous infusion. The dosage and frequency vary depending on the specific trial, but it is typically given every two or three weeks, with doses ranging from 0.1 mg/kg to 9.0 mg/kg.
  • What are the main objectives of the Osteodex clinical trials? The main objectives of the Osteodex clinical trials include determining the maximum tolerable dose, evaluating safety and tolerability, assessing the drug's effects on bone metabolism markers, measuring overall survival, and analyzing quality of life improvements in patients.
  • How long do the Osteodex clinical trials typically last? The duration of Osteodex clinical trials varies, but they generally last between 20 to 30 weeks for the initial treatment and follow-up period. Some trials also include long-term follow-up phases that can extend up to 24 months or more.

Ongoing Clinical Trials on Osteodex

  • Study on the Safety and Tolerability of OsteoDex for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1
    Investigated drugs:
    Sweden

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (CRPC): An advanced form of prostate cancer that continues to progress despite treatments that lower testosterone levels. It has spread beyond the prostate to other parts of the body, often to the bones.
  • Multiple Myeloma: A type of blood cancer that affects plasma cells, a type of white blood cell. It often involves bone damage and can lead to bone pain and fractures.
  • Poly-bisphosphonate: A class of drugs that help prevent the loss of bone density. In the case of Osteodex, it's a combination of multiple bisphosphonate molecules designed to target bone metabolism.
  • Bone Metabolism Markers: Substances in the blood or urine that indicate the rate of bone formation or breakdown. Common markers include alkaline phosphatase (ALP), P1NP, CTX, and osteocalcin.
  • PSA (Prostate-Specific Antigen): A protein produced by the prostate gland. Elevated levels in the blood can indicate prostate cancer or other prostate conditions.
  • FACT-P: Functional Assessment of Cancer Therapy – Prostate, a questionnaire used to assess quality of life in prostate cancer patients.
  • EQ-5D-5L: A standardized instrument used to measure health-related quality of life across various health conditions.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a dosage reduction.
  • Data Monitoring Committee (DMC): An independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.

References

  1. https://clinicaltrials.gov/study/NCT01595087
  2. https://clinicaltrials.gov/study/NCT02825628
  3. https://clinicaltrials.gov/study/NCT06616389
  4. https://clinicaltrials.gov/study/NCT02378870